Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 2
2007 2
2009 1
2011 6
2012 2
2013 3
2014 2
2015 2
2016 4
2017 2
2018 1
2019 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.
Olson CM, Jiang B, Erb MA, Liang Y, Doctor ZM, Zhang Z, Zhang T, Kwiatkowski N, Boukhali M, Green JL, Haas W, Nomanbhoy T, Fischer ES, Young RA, Bradner JE, Winter GE, Gray NS. Olson CM, et al. Among authors: nomanbhoy t. Nat Chem Biol. 2018 Feb;14(2):163-170. doi: 10.1038/nchembio.2538. Epub 2017 Dec 18. Nat Chem Biol. 2018. PMID: 29251720 Free PMC article.
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.
Johnson Z, Tarantelli C, Civanelli E, Cascione L, Spriano F, Fraser A, Shah P, Nomanbhoy T, Napoli S, Rinaldi A, Niewola-Staszkowska K, Lahn M, Perrin D, Wenes M, Migliorini D, Bertoni F, van der Veen L, Di Conza G. Johnson Z, et al. Among authors: nomanbhoy t. Cancer Res Commun. 2023 Apr 14;3(4):576-591. doi: 10.1158/2767-9764.CRC-22-0477. eCollection 2023 Apr. Cancer Res Commun. 2023. PMID: 37066023 Free PMC article.
Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
Green JL, Okerberg ES, Sejd J, Palafox M, Monserrat L, Alemayehu S, Wu J, Sykes M, Aban A, Serra V, Nomanbhoy T. Green JL, et al. Among authors: nomanbhoy t. Mol Cancer Ther. 2019 Apr;18(4):771-779. doi: 10.1158/1535-7163.MCT-18-0755. Epub 2019 Mar 5. Mol Cancer Ther. 2019. PMID: 30837298
High-resolution crystal structure of human asparagine synthetase enables analysis of inhibitor binding and selectivity.
Zhu W, Radadiya A, Bisson C, Wenzel S, Nordin BE, Martínez-Márquez F, Imasaki T, Sedelnikova SE, Coricello A, Baumann P, Berry AH, Nomanbhoy TK, Kozarich JW, Jin Y, Rice DW, Takagi Y, Richards NGJ. Zhu W, et al. Among authors: nomanbhoy tk. Commun Biol. 2019 Sep 17;2:345. doi: 10.1038/s42003-019-0587-z. eCollection 2019. Commun Biol. 2019. PMID: 31552298 Free PMC article.
Discovery of potent and selective covalent inhibitors of JNK.
Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, Xie T, Marto JA, Kim N, Sim T, Laughlin JD, Park H, LoGrasso PV, Patricelli M, Nomanbhoy TK, Sorger PK, Alessi DR, Gray NS. Zhang T, et al. Among authors: nomanbhoy tk. Chem Biol. 2012 Jan 27;19(1):140-54. doi: 10.1016/j.chembiol.2011.11.010. Chem Biol. 2012. PMID: 22284361 Free PMC article.
34 results